Understanding liver transplantation outcomes through the lens of its tissue-resident immunobiome by Prosser, AC, Klenerman, P, Lucas, M

“…The importance of donor- and recipient-derived TRLs after transplantation is becoming increasingly recognized, although it has not been examined in detail after liver transplantation. This review summarizes the evidence for the roles of TRLs in liver transplant immunology, focusing on their features, functions, and potential for their harnessing to improve transplant outcomes.…”

Injectable cell transplantation system for cytokine-based cancer immunotherapy by Gerard Nathanael Adrianus.

Get full text

Clinical course, immunogenicity, and efficacy of BNT162b2 mRNA vaccination against SARS-CoV-2 infection in liver transplant recipients by Tan, Eunice X., Lim, Wen Hui, Thong, Elizabeth, Chavatte, Jean-Marc, Zhang, Jinyan, Lim, Jonathan, Jin, Jocelyn Y., Lim, Daniel R. X., Kang, Jaclyn Y. T., Tang, Ansel Shao Pin, Chan, Kai En, Tan, Caitlyn, Tan, Shi Ni, Nah, Benjamin, Huang, Daniel Q., Wang, Lin-Fa, Tambyah, Paul A., Somani, Jyoti, Young, Barnaby Edward, Muthiah, Mark D.

Subjects: Get full text

Naïve B cells followed by aquaporin-4 antibodies characterise the onset of neuromyelitis optica: evidence from stem cell transplantation by McNaughton, P, Payne, R, Michael, S, Leahy, T, Nicols, A, Fower, A, Hambleton, S, Pang, K, Gennery, A, Irani, SR

Partially Oxidized Alginate as a Biodegradable Carrier for Glucose‐Responsive Insulin Delivery and Islet Cell Replacement Therapy by Volpatti, Lisa R, Bochenek, Matthew A, Facklam, Amanda L, Burns, Delaney M, MacIsaac, Corina, Morgart, Alexander, Walters, Benjamin, Langer, Robert, Anderson, Daniel G

“…Two approaches towards this goal are glucose‐responsive insulin delivery and islet cell transplantation therapy. Here, biodegradable, partially oxidized alginate carriers for glucose‐responsive nanoparticles or islet cells are developed. …”
Get full text

Hepatogenesis of murine induced pluripotent stem cells in 3D micro-cavitary hydrogel system for liver regeneration by Koh, Mei Shan

“…Currently, the only effective option to treat end stage liver disease is orthopedic liver transplantation. Yet, millions of patient died while waiting for suitable hepatocyte tissue donations. …”
Get full text

Injectable transplantation system for anticancer in-situ cell therapy by Sheng, Nan.

“…In this project, we are aiming to evaluate the feasibility of remodeling immunosurveillance into the tumor site, with an engineering, more particularly, functional materials-mediated cell therapeutic strategy by designing an injectable cell transplantation system for anti-cancer therapy. The RAW 264.7 cells are encapsulated in dual-layer hydrogel composite which is in injectable size. …”
Get full text

Ex vivo expansion and genetic manipulation of mouse hematopoietic stem cells in polyvinyl alcohol-based cultures by Khoo, HM, Meaker, GA, Wilkinson, AC

“…HSCs are used clinically in stem cell transplantation therapies, which represent curative treatment for a range of blood diseases. …”

Materials approaches for next-generation encapsulated cell therapies by Krishnan, Siddharth R., Langer, Robert, Anderson, Daniel G.

“…However, attack from the host immune system represents a major challenge, requiring chronic immunosuppression to enable long-lived cell transplantation in vivo. Encapsulating cells in engineered biomaterials capable of excluding components of the host immune system while allowing for the transport of therapeutic proteins, oxygen, nutrients, metabolites, and waste products represents a potential solution. …”
Get full text

Targeted hematopoietic stem cell depletion through SCF-blockade by Chan, Yan Y., Ho, Pui Y., Dib, Carla, Swartzrock, Leah, Rayburn, Maire, Willner, Hana, Ko, Ethan, Ho, Katie, Down, Julian D., Wilkinson, Adam C., Nakauchi, Hiro, Denis, Morgane, Cool, Taylor, Czechowicz, Agnieszka

“…Abstract Background Hematopoietic stem cell transplantation (HSCT) is a curative treatment for many diverse blood and immune diseases. …”
Get full text

Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study by Sallman, DA, Al Malki, MM, Asch, AS, Wang, ES, Jurcic, JG, Bradley, TJ, Flinn, IW, Pollyea, DA, Kambhampati, S, Tanaka, TN, Zeidner, JF, Garcia-Manero, G, Jeyakumar, D, Komrokji, R, Lancet, J, Kantarjian, HM, Gu, L, Zhang, Y, Tan, A, Chao, M, O'Hear, C, Ramsingh, G, Lal, I, Vyas, P, Daver, NG

“…Thirty-four patients (36%) had allogeneic stem-cell transplant with 77% 2-year OS.</p> <br> <p><strong>Conclusion:</strong> Magrolimab + azacitidine was well tolerated with promising efficacy in patients with untreated higher-risk MDS, including those with TP53 mutations. …”